Coherus Plans 30% Staff Cut To Lower The Sales Needed To Cover Core Costs
Quarterly drug sales missed management's growth target, while cash runway excludes potential savings, milestones and overseas deals.
Coherus Oncology, which sells the cancer drug LOQTORZI, plans a projected 30% workforce cut to reduce the quarterly sales needed to cover its core costs. Chief Executive Officer Dennis "Denny" Lanfear outlined the plan on the company's earnings call Monday, targeting financial self-sufficiency by the end of 2027 even as management warned that cash runway was less than 12 months without potential financial benefits.
A Lower Bar, Still Above Sales
Chief Financial Officer Bryan McMichael said the cuts would take staffing from about 140 full-time employees to about 100 this month. Management expects recurring savings averaging $6 million–$7 million a quarter, with most of that savings rate achieved within two quarters.
Coherus expects the reductions to lower the quarterly LOQTORZI sales needed to cover core costs, excluding development spending, to $25 million–$30 million from $30 million–$35 million. McMichael said the company would retain "substantially all the commercial organizations" while reducing staff across the business.
Sales have some distance to travel. Chief Commercial Officer Sameer Goregaoker reported third-quarter net sales of $14 million, up 25% from a year earlier but just 3% from the previous quarter. Management had targeted quarterly growth of 10%–15%; Goregaoker attributed the shortfall to slower new patient starts in some territories.
McMichael revised the annual revenue outlook to $54 million–$57 million because sales were more uneven than management anticipated. Goregaoker still expects a $15 million sales quarter in the fourth quarter and said the company remains on track to reach peak market share by 2028.
Cash Depends On More Than Cuts
Coherus ended the third quarter with $83.6 million in cash, cash equivalents and investments, down $21.7 million from $105.3 million at the end of the second quarter. Operating cash use was $34 million, a 43% decline from the quarterly average in the first half of 2026.
McMichael attributed the slower cash use primarily to reduced payments against obligations tied to the divested biosimilars business. A previously announced refinancing also helped: Coherus paid off a $38.7 million term loan using a new $55 million loan that closed during the quarter, adding a net $11.5 million to cash.
The company's quarterly report nevertheless carries a going-concern warning about its ability to keep operating. McMichael said runway was less than 12 months from Monday's filing date when potential cost savings, milestone payments and overseas deal proceeds were excluded.
One possible payment is a $37.5 million milestone from the Udenica sale. Reported sales came close enough to the earn-out threshold that McMichael said a modest audit adjustment could trigger it. Coherus is exercising its audit and contractual rights to review the results; the payment remains potential. The company expects the report for a second $37.5 million milestone after the first quarter of 2027.
Spending is already declining. Third-quarter research and development expense from continuing operations fell to $22.6 million from $27.3 million a year earlier. Selling, general and administrative expense fell to $21.2 million from $24.9 million. Management reiterated its full-year combined operating-expense forecast of $170 million–$175 million.
The transition has also produced losses: Coherus's second-quarter loss was $33.35 million. Its market value was $119 million as of Monday at 6:01 p.m. ET.
Esophageal Cancer Takes Development Priority
Coherus completed its exit from biosimilars in 2025. Its oncology business sells LOQTORZI, an antibody that blocks the PD-1 protein to help the immune system attack tumors, approved by the FDA for nasopharyngeal carcinoma, a cancer of the upper throat. Its mid-stage drug candidates include tagmokitug and casdozokitug.
Lanfear said a broad clinical program involving more than 120 patients had supplied the evidence to select tagmokitug's development focus and dose. Management reported its esophageal-cancer priority on October 28 and now plans to concentrate development there, pursuing patients whose disease has progressed after initial treatment before advancing the first-line opportunity.
Chief Medical Officer Rosh Dias described nine evaluable second-line patients receiving 700 milligrams of tagmokitug with toripalimab. Three had confirmed partial tumor responses, a 33.3% response rate; including an unconfirmed response brought the figure to 44.4%, compared with a chemotherapy-only benchmark of around 10%. The randomized study had treated 22 patients across two doses. Dias said the 300-milligram group had no responses and all patients progressed by four months.
Chief Development and Regulatory Officer Theresa Lavallee said Coherus plans FDA discussions early in 2027 to settle the dose and a randomized study against chemotherapy. Management is exploring whether response durability could support accelerated approval; approval remains a development objective.
Coherus is also seeking overseas partners whose upfront payments could offset clinical expenses and whose funding could support registration trials in their territories. Casdozokitug has not been deprioritized, Lanfear said, with further insights possible in the first quarter as its data mature.
Prescribing Habits Are The Commercial Test
Lanfear put LOQTORZI's market share at approximately 20%–22%, with about 30% of patients receiving chemotherapy alone and 40% receiving off-label immunotherapies. He cited survival of 64.8 months with LOQTORZI plus chemotherapy versus 33.7 months with chemotherapy alone as the case for wider use.
An Oppenheimer analyst asked how quarterly sales could move from $14 million to the new funding threshold. Goregaoker pointed to rare-disease patient flows and prescribing habits: physicians may agree to use the drug but forget when an eligible patient arrives months later.
Coherus is using claims-based alerts to reach physicians, working with large clinical organizations and academic centers to identify eligible patients, and expanding payer preferences for LOQTORZI. Goregaoker said its share of addressable patients where payer partnerships operate is approximately double the national average.
The commercial team also has evidence of changing physician views. In a company survey of academic and community oncologists, 75% viewed LOQTORZI as the standard of care, versus fewer than 35% for off-label immunotherapies; 57% knew its six-year survival data. Those perceptions still have to become prescriptions to meet management's sales goals.
Coherus's manufacturing transfer from China to the United States was completed in the third quarter, while the FDA's action date for the drug-product application is November 30. Management is counting on lower transition costs, narrower development spending and higher LOQTORZI sales to support its 2027 self-funding target.
Sources
- Coherus Oncology: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Coherus BioSciences Non-GAAP EPS of -$0.20 beats by $0.01, revenue of $14.27M misses by $1.66M (CHRS:NASDAQ) | Seeking Alpha — seekingalpha.com
- Coherus Oncology, Inc. (CHRS) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance
- Coherus Oncology Reports Third Quarter 2026 Financial — globenewswire.com